Clinical Trials Logo

Clinical Trial Summary

1. To evaluate the effect of the platelet rich plasma on the take of split thickness skin graft and its early and late results in resurfacing of post burn raw areas. 2. To evaluate the effect of PRP on wound healing on skin graft donor site.


Clinical Trial Description

Burn injuries involve tissue destruction due to energy transfer,The burn injuries can be caused by heat from hot liquids, solids or fire, an less common causes are friction, heat, chemical or electric sources The treatment of burns is complex due to the combination of hypermetabolic physiological response and the need for good functional and cosmetic recovery. Split thickness skin grafts (STSGs) are commonly used to resurface large areas of Post burn raw areas. The time to complete wound healing ranged from 2 to 75 days. Factors that significantly affected time to complete wound healing were graft loss by seroma, presence of hypergranulation tissue, premorbid conditions, and total body surface area burned. Generally, skin graft undertakes three steps for healing: anchorage, inosculation, and maturation. Haematoma, shearing, and infection on recipient sites of skin graft can reduce skin graft take, and even lead to skin graft loss. Platelet-rich plasma (PRP) is an autologous blood-derived biomaterial that is enriched with a 2- to 6-fold concentration of platelets in comparison to normal human platelet concentration. Multiple growth factors and bioactive proteins are stored in α-granules of platelets. These growth factors can promote proliferation of endothelial cells, epithelial cells as well as fibroblasts, and increase angiogenesis. The potential clinical application of PRP in skin graft might rely on its haemostasis, adhesive, antibacterial and healing properties. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05996614
Study type Interventional
Source Assiut University
Contact Ibrahim Ragab Ibrahim, master
Phone 00201060865454
Email himo_nimo9@icloud.com
Status Not yet recruiting
Phase N/A
Start date October 1, 2023
Completion date February 2025

See also
  Status Clinical Trial Phase
Completed NCT04044014 - Gellan Contact Study N/A